ebastine / Generic mfg. - LARVOL DELTA

Evaluation of photochemical behavior of ebastine and elucidation of its photoproducts. (PubMed, J Pharm Biomed Anal) - "Finally, in silico toxicity prediction was performed for the estimation of toxicological potencies of EB photoproducts, suggesting the nature of EB might be changed by the photodegradation. In conclusion, two novel EB photoproducts were clarified and their formation mechanisms were proposed, which might make it possible to the better understanding of EB photodegradability."

Journal • Allergy • Immunology

Case Report: Delayed-type hypersensitivity reaction to meropenem in an elderly patient-successful management with imipenem-cilastatin. (PubMed, Front Med (Lausanne)) - "This allergic reaction was immediately managed with calcium gluconate, dexamethasone sodium phosphate, and ebastine...Following a 14-day antimicrobial therapy, initially with imipenem-cilastatin and subsequently with amoxicillin-clavulanate potassium tablets, the patient's skin rashes gradually subsided and the infection was successfully controlled. This case highlights the risk of DTH reaction induced by meropenem in clinical settings. Clinicians should remain vigilant for DTH reactions during meropenem therapy and cautiously consider alternative carbapenems such as imipenem-cilastatin."

Journal • Allergy • Dermatology • Immunology • Infectious Disease

A STRANGE CASE OF HYPOKALAEMIA IN A TEENAGER WITH EBASTINE TREATMENT (ESPN 2025) - "We reported the case of a 13 years-old boy with severe and symptomatic hypokalaemia three days after an ebastine initiation treatment with a normal dose. Preliminary plasma and urinary tests suggested a renal waste of potassium without any other electrolytes disorder. Metabolic disorders were corrected with only potassium supplementation and discontinuation of ebastine treatment witch suggested an iatrogenic cause of hypokalaemia."

Clinical • Asthma • Cardiovascular • Hypertension • Immunology • Metabolic Disorders • Pediatrics • Respiratory Diseases

Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta Analysis. (PubMed, Int Arch Allergy Immunol) - "Ebastine ranked first in the total symptom score(standardized mean difference(SMD) -2.80[95% confidence interval(CI):-5.12 to -0.47]) and pruritus score (SMD -1.10[95%CI: -2.06 to -0.13]), while olopatadine ranked first in the wheal score (SMD -0.84 [95%CI :-1.37 to -0.32]).Bepotastine besilate had a significantly lower incidence of somnolence in adverse events (odds ratio(OR) 0.15[95%CI: 0.03 to 0.69]) than other sgAHs. There are no meaningful differences in safety risks between different second-generation antihistamines. Keywords: second-generation antihistamines; Chronic urticaria; Total symptom score; Adverse events; Network meta-analysis."

Clinical • HEOR • Journal • Retrospective data • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Pruritus • Urticaria

Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome (clinicaltrials.gov) - P2/3 | N=60 | Recruiting | Sponsor: Md. Hazrat Ali | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder

Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome (clinicaltrials.gov) - P2/3 | N=60 | Not yet recruiting | Sponsor: Md. Hazrat Ali

New P2/3 trial • Gastrointestinal Disorder

Idiopathic multicentric Castleman disease resembling autoimmune diseases: A case report. (PubMed, Medicine (Baltimore)) - "This case highlights the rarity and uniqueness of iMCD, which can easily be confused with lymphadenopathy caused by autoimmune diseases (e.g., rheumatoid arthritis-related lymphadenopathy, IgG4-related diseases). Clinicians should consider lymph node histology in conjunction with clinical and serological findings, as well as imaging results, for accurate diagnosis."

IO biomarker • Journal • Dermatology • Dermatopathology • Fatigue • Hematological Disorders • Immunology • Inflammatory Arthritis • Pruritus • Rare Diseases • Rheumatoid Arthritis • Rheumatology • Thrombocytosis • CD38 • CRP • IL6 • SDC1

Facial edema after covid-19 ameliorated by acupuncture: A CARE-compliant case report. (PubMed, Medicine (Baltimore)) - "This case suggests that acupuncture may be an effective alternative therapy for superficial skin inflammation and edema caused by viral infections like COVID-19. Further studies are warranted to explore acupuncture's role in managing post-viral inflammatory conditions."

Journal • Dermatitis • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pain

An example of drug repurposing: ebastine in combination with docetaxel as a treatment for metastatic castration-resistant prostate cancer-the EXUROC prostate study, a clinical trial protocol. (PubMed, BMC Urol) - No abstract available

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Bactericidal and anti-biofilm activity of ebastine against Staphylococcus aureus. (PubMed, Lett Appl Microbiol) - "Furthermore, safety evaluations showed that ebastine exhibited limited toxicity to mammalian cells, with negligible hemolytic effects and good overall safety profiles. This study provided new insights into the potential applications of ebastine in the field of antimicrobial therapy, highlighting its promise as a non-traditional antibacterial agent."

Journal • Infectious Disease

Development and Optimization of Oral Dissolution Films for Enhanced Delivery of Ebastine-Loaded Solid Lipid Nanoparticles. (PubMed, Int J Nanomedicine) - "The developed system demonstrates enhanced solubility, stability, and bioavailability of ebastine, offering a promising alternative to traditional oral tablets, with potential advantages in patient compliance and rapid drug onset. Therefore, the ODFs containing SLNs can be considered as an efficient approach for EBT administration."

Journal • Allergy • Immunology

EBASTINE INTERRUPTS THE HISTAMINERGIC-NEUROTROPHIN LOOP TO INHIBIT PANCREATIC CANCER PROGRESSION AND MODULATE THE IMMUNE MICROENVIRONMENT UNDER CHRONIC STRESS CONDITIONS (DDW 2025) - No abstract available

Oncology • Pancreatic Cancer • Solid Tumor

5310: Pancreatitis and Pancreatic Cancer: Inflammation, Fibrogenesis and Immunology (DDW 2025) - "Description: This session will explore the complex interplay between inflammation, fibrogenesis, and immunology in the context of pancreatitis and pancreatic cancer. Presentations will cover topics such as the role of TLR2 in acute pancreatitis, the impact of ebastine on pancreatic cancer progression, and the mechanisms driving immune evasion in pancreatic ductal adenocarcinoma.Learning Objectives:• Describe the Role of Inflammation in Pancreatitis and Pancreatic Cancer• Explore Mechanisms of Immune Evasion and Tumor Progression• Discuss Diagnostic and Therapeutic Approaches"

Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Pancreatitis • Solid Tumor • TLR2

Ebastine in combination with low-dose antidepressants for refractory irritable bowel syndrome: A randomized controlled trial. (PubMed, Technol Health Care) - "They were administered with ebastine (Group A) or ebastine combined with flupentixol and melitracen (Group B) for 4 weeks. After treatment, the serum levels of D-LAC and I-FABP were significantly lower in Group B than in Group A.ConclusionRefractory IBS patients showed certain psychological abnormalities. Ebastine combined with antidepressants exhibited more obvious benefits on QOL, sleep quality, and SSS, with significant improvements in psychological status and intestinal permeability in refractory IBS patients."

Journal • CNS Disorders • Depression • Gastrointestinal Disorder • Mood Disorders • Psychiatry

Identification of effective synthetic molecules against viral-induced cytokine release syndrome using in silico and in vitro approaches. (PubMed, Mol Divers) - "Six potential 3-CLpro inhibitors were identified by molecular docking using MOE software, including ebastine (1), orlistat (2), atracurium besylate (3), piperaquine phosphate (4), valsartan (5), and acarbose (6), among which 1-3 binds strongly to the target protein with binding affinity of - 8.22, - 9.12, and - 7.81, kcal/mol, respectively. This study demonstrates the potential of pre-existing drugs to ameliorate the cytokine storm and oxidative damage with simultaneous anti-viral effects. The data provide pre-clinical support to develop these drugs as potential therapeutic agent against ARDS."

Journal • Preclinical • Acute Respiratory Distress Syndrome • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • CSF2 • IFNG • IL1B • IL2 • IL6 • TNFA

Two Cases of Acquired Reactive Perforating Collagenosis in Hemodialysis Patients. (PubMed, Semin Dial) - "Two patients were treated with oral thalidomide and ebastine, local application of fluticasone propionate cream, and enhanced dialysis. We report for the first time that ARPC in patients with hemodialysis could be improved by oral thalidomide and antihistamines and local application of steroid. This report provides reference for guiding the understanding of ARPC and the new treatment of ARPC in hemodialysis patients."

Journal • Cardiovascular • Chronic Kidney Disease • Dermatology • Diabetes • Endocrine Disorders • Hypertension • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

Ebastine-mediated destabilization of E3 ligase MKRN1 protects against metabolic dysfunction-associated steatohepatitis. (PubMed, Cell Mol Life Sci) - "This enhances AMPK stability and activity, suppressing lipid accumulation, inflammation, and fibrosis. Moreover, the knockout of Mkrn1 mice decreased the risk of MASH, suggesting that ebastine could be a promising therapeutic agent for the treatment of MASH."

Journal • Fibrosis • Genetic Disorders • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Oncology • Solid Tumor • Targeted Protein Degradation

S6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance. (PubMed, Int J Biol Sci) - " We identified a novel derivative of the antihistamine drug ebastine, designated Super-ebastine (Super-EBS), that inhibited the viability of cancer cells representing diverse KRAS and EGFR driver mutations and models of plasticity and treatment resistance...The essential role of S6K1 in the action of Super-EBS was recapitulated in xenografts, and knockout of S6K1 abrogated tumor growth in mice. S6K1 is a therapeutic vulnerability in tumors exhibiting intrinsic and/or acquired resistance to treatment."

Journal • Oncology • CDC42 • EGFR • KRAS • RPS6KB1

Prednisolone versus antihistamine for allergic rhinitis: No significant difference found in randomized trial. (PubMed, Clin Transl Allergy) - "Prednisolone tablets did not show superior efficacy over antihistamine tablets in reducing symptoms or medication usage in tree pollen-induced AR. These results suggest that systemic corticosteroids may not provide additional benefits over antihistamines, and clinicians should prioritize individualized treatment based on patient preferences and tolerability."

Journal • Allergic Rhinitis • Immunology • Inflammation

Exploring α-Lipoic Acid Based Thermoplastic Silicone Adhesive: Towards Sustainable and Green Recycling. (PubMed, Polymers (Basel)) - "The shear strength of the LASA90 presented strong adhesion (up to 88 kPa) on various substrates including steel, aluminum, PET, and PTFE...The rheology, TG-DTA, DSC, and 1H NMR showed that the degradation of the LASA occurred at 150 °C via the retro-ROP of the five-membered disulfide ring, indicating their recyclability after usage. Conclusively, we envision that a silicone adhesive based on α-lipoic acid as a natural linker is more sustainable than conventional silicone thermosets because of its desired properties, strong adhesion, reversibility, and on-demand heat degradation."

Journal

Ebastine Interrupts the Histaminergic Neurons-Pancreatic Cancer Communication Loop to Inhibit Pancreatic Cancer Progression Under Chronic Stress Conditions (APA-JPS-CAP-IAP 2024) - No abstract available

Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Analyzing the clinical efficacy and safety of levocetirizine based on its receptor occupancy, intraclass comparison and role in the treatment of CSU: an AROG consensus statement. (PubMed, Expert Rev Clin Pharmacol) - "The marked receptor occupancy translates to better efficacy as compared to similarly dosed SGAH and the lower cost of the molecule makes it an appropriate drug for chronic use. Receptor occupancy should serve as the basis of intra-class head-to-head trials for CSU."

Journal • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Ebastine Versus Mebeverine in IBS Patients (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Guy Boeckxstaens | Trial completion date: Jan 2027 ➔ Jan 2028 | Trial primary completion date: Oct 2026 ➔ Oct 2027

Trial completion date • Trial primary completion date • Gastrointestinal Disorder

Acidic sphingomyelinase interactions with lysosomal membranes and cation amphiphilic drugs: A molecular dynamics investigation. (PubMed, Comput Struct Biotechnol J) - "Our study, leveraging all-atom explicit solvent molecular dynamics simulations, delves into the interaction of glycosylated ASM with the lysosomal membrane and the effects of CAD representatives, i.e., ebastine, hydroxyebastine and loratadine, on the membrane and ASM. CADs also interfere with the association of ASM with the membrane at the level of a loop in the catalytic domain engaging in membrane interactions. Our computational approach, applicable to various CADs or membrane compositions, provides insights into ASM and CAD interaction with the membrane, offering a valuable tool for future studies."

Journal • Oncology

Cost-effectiveness Analysis of Second-Generation Antihistamine 1 Receptor Blockers and Japanese Kampo Shoseiryuto for Treating Perennial Allergic Rhinitis in Outpatient Settings in Japan. (PubMed, Hosp Pharm) - " The most cost- and clinically effective SGAs were determined from a list of 6 SGAs (bepotastine, 10 mg; cetirizine, 10 mg; ebastine, 10 mg; epinastine, 20 mg; loratadine, 10 mg; and olopatadine, 5 mg) together with shoseiryuto, using the overall improvement rate through a model-based analysis. Ebastine (10 mg) was the most cost-effective treatment strategy for PAR among the agents evaluated in this study. This insight could aid in establishing an appropriate formulary for treating PAR in hospitals and communities."

Cost effectiveness • HEOR • Journal • Allergic Rhinitis • Immunology • Inflammation